CL2022003716A1 - Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida - Google Patents

Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida

Info

Publication number
CL2022003716A1
CL2022003716A1 CL2022003716A CL2022003716A CL2022003716A1 CL 2022003716 A1 CL2022003716 A1 CL 2022003716A1 CL 2022003716 A CL2022003716 A CL 2022003716A CL 2022003716 A CL2022003716 A CL 2022003716A CL 2022003716 A1 CL2022003716 A1 CL 2022003716A1
Authority
CL
Chile
Prior art keywords
biphenyl
heteroaryl
cancer treatment
treatment methods
amide derivatives
Prior art date
Application number
CL2022003716A
Other languages
English (en)
Spanish (es)
Inventor
Li Shijie
Vilalta-Colomer Marta
Zeng Yibin
Zhang Penglie
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of CL2022003716A1 publication Critical patent/CL2022003716A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2022003716A 2020-06-23 2022-12-22 Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida CL2022003716A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063042807P 2020-06-23 2020-06-23

Publications (1)

Publication Number Publication Date
CL2022003716A1 true CL2022003716A1 (es) 2023-06-30

Family

ID=79022859

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003716A CL2022003716A1 (es) 2020-06-23 2022-12-22 Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida

Country Status (14)

Country Link
US (3) US20210393759A1 (https=)
EP (1) EP4167991A4 (https=)
JP (1) JP7804596B2 (https=)
KR (1) KR20230040993A (https=)
CN (1) CN116472045B (https=)
AU (1) AU2021297216B2 (https=)
BR (1) BR112022026397A2 (https=)
CA (1) CA3187605A1 (https=)
CL (1) CL2022003716A1 (https=)
CO (1) CO2023000703A2 (https=)
IL (1) IL299206A (https=)
MX (1) MX2022016554A (https=)
TW (1) TW202216694A (https=)
WO (1) WO2021262627A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10392405B2 (en) 2017-08-08 2019-08-27 Chemocentryx, Inc. Macrocyclic immunomodulators
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
WO2020232256A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
JP7736678B2 (ja) 2019-10-16 2025-09-09 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド
ES3064674T3 (en) 2019-10-16 2026-04-28 Chemocentryx Inc Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102448938A (zh) * 2009-03-27 2012-05-09 阿迪生物科学公司 作为mek抑制剂的二氢吡啶磺酰胺和二氢吡啶硫酰胺
SG11201402004YA (en) * 2011-11-14 2014-05-29 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors
EP2788000B1 (en) * 2011-12-06 2018-05-30 Merck Sharp & Dohme Corp. Pyrrolopyrimidines as janus kinase inhibitors
WO2018119221A1 (en) * 2016-12-22 2018-06-28 Incyte Corporation Pyridine derivatives as immunomodulators
JP7101678B2 (ja) * 2016-12-22 2022-07-15 インサイト・コーポレイション 免疫調節剤としての複素環式化合物
CN106674136B (zh) * 2016-12-23 2019-07-02 中国医科大学 嘧啶类抗肿瘤化合物及其制备方法
US10919852B2 (en) * 2017-07-28 2021-02-16 Chemocentryx, Inc. Immunomodulator compounds
CA3092362A1 (en) * 2017-10-19 2019-04-25 Tempest Therapeutics, Inc. Picolinamide compounds
CR20200347A (es) * 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
US10568874B2 (en) * 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
WO2020232256A1 (en) 2019-05-15 2020-11-19 Chemocentryx, Inc. Triaryl compounds for treatment of pd-l1 diseases
JP7736678B2 (ja) * 2019-10-16 2025-09-09 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド

Also Published As

Publication number Publication date
TW202216694A (zh) 2022-05-01
US20240115682A1 (en) 2024-04-11
AU2021297216B2 (en) 2025-10-16
BR112022026397A2 (pt) 2023-03-14
AU2021297216A1 (en) 2023-02-02
IL299206A (en) 2023-02-01
CO2023000703A2 (es) 2023-01-26
US20210393759A1 (en) 2021-12-23
CN116472045A (zh) 2023-07-21
WO2021262627A1 (en) 2021-12-30
CN116472045B (zh) 2025-05-13
CA3187605A1 (en) 2021-12-30
US20250090646A1 (en) 2025-03-20
MX2022016554A (es) 2023-04-10
EP4167991A4 (en) 2024-07-24
JP7804596B2 (ja) 2026-01-22
KR20230040993A (ko) 2023-03-23
EP4167991A1 (en) 2023-04-26
JP2023531970A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
CO2023000703A2 (es) Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida
CO2021017504A2 (es) Derivados de benzisoxazol sulfonamida
CL2023003491A1 (es) Derivados de triazina y su uso en el tratamiento del cáncer
CO2023015037A2 (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
UY39303A (es) Inhibidores de mutación her2
MX2023013987A (es) Inhibidores alostéricos de cromenona de la fosfoinosítido 3-quinasa (pi3k) para el tratamiento contra el cáncer.
MX2020010676A (es) Derivados de pladeniolida como agentes dirigidos al espliceosoma para tratar el cancer.
AR125331A1 (es) Combinación que comprende ribociclib y amcenestrant
UY39193A (es) Compuestos de azalactama como inhibidores de hpk1
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
MX2024003028A (es) Derivados de 6 aza quinolina y usos relacionados.
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
DOP2025000212A (es) Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades
MX2025010161A (es) Conjugados de anticuerpo-farmaco que comprenden derivados de trabectedina y lurbinectedina
CO2025018532A2 (es) Un método para el tratamiento de tumores sólidos con un conjugado anticuerpo-fármaco dirigido a claudina 18.2
CO2021011319A2 (es) Tratamientos combinados para su uso en el tratamiento del cáncer
CO2023012702A2 (es) Derivados de diazepina útiles en el tratamiento de clostridium difficile
MX2024006732A (es) Conjugado de anticuerpo anti-trop2 humano - fármaco de camptotecina y uso médico del mismo.
CO2021011328A2 (es) Derivados de 2h-indazol como agentes terapéuticos para cánceres cerebrales y metástasis cerebrales
CO2026000866A2 (es) Cocristal de un inhibidor de idh1, proceso de preparación del mismo, composiciones farmacéuticas del mismo, y métodos de tratamiento que implican el mismo
UY39532A (es) Compuestos de (aza)benzotiazolil-pirazol sustituidos
AR118933A1 (es) Dosificación del inhibidor de kras para el tratamiento de cánceres